Biocompatibility of injectable chitosan-phospholipid implant systems

Biomaterials

Volumn 30, Issue 23-24, 2009, Pages 3818-3824

  De Souza, Raquel ^a   Zahedi, Payam ^a   Allen, Christine J ^a   Piquette Miller, Micheline ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biocompatibility; Chitosan; Cytotoxicity; Injectable; Phospholipid

Indexed keywords

BODY WEIGHT; CELL VIABILITY; HELA CELL LINE; HISTOLOGICAL EXAMINATION; IN-VITRO; IN-VIVO; INJECTABLE; INJECTABLE BIOMATERIALS; INTERLEUKIN-6; INTRAPERITONEALLY; INVASIVENESS; PATIENT COMPLIANCE; THERAPEUTIC APPLICATION;

ALDEHYDES; ANIMALS; BIOCOMPATIBILITY; BIODEGRADATION; BIOLOGICAL MATERIALS; CELL CULTURE; CHITIN; CHITOSAN; CHLORINE COMPOUNDS; CYTOTOXICITY; GELATION; PHOSPHOLIPIDS; TISSUE ENGINEERING;

GELS;

CHITOSAN; LAURIC ACID DERIVATIVE; PHOSPHOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BIOCOMPATIBILITY; BIODEGRADATION; CELL STRAIN L 929; CELL VIABILITY; CONTROL GROUP; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HELA CELL; HISTOLOGY; HUMAN; HUMAN CELL; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; LIVER EXAMINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN EXAMINATION; TOXICITY; WEIGHT CHANGE;

ANIMALS; BEHAVIOR, ANIMAL; BIOCOMPATIBLE MATERIALS; BODY WEIGHT; CELL LINE; CELL SURVIVAL; CHITOSAN; FEMALE; HELA CELLS; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; LIVER; MICE; PHOSPHOLIPIDS; SPLEEN; TISSUE ENGINEERING;

ANIMALIA; MUS;

EID: 67349093532     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.04.003     Document Type: Article

References (67)

1. Putney S.D., and Burke P.A. Improved protein therapeutics with sustained-release formulations. Nat Biotechnol 16 5 (1998) 153-7
2. Temenoff J.S., and Mikos A.G. Injectable biodegradable materials for orthopedic tissue engineering. Biomaterials 21 23 (2000) 2405-2412
3. Hatefi A., and Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release 80 1-3 (2002) 9-28
4. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2 5 (2003) 347-360
5. Lee K.Y., and Mooney D.J. Hydrogels for tissue engineering. Chem Rev 101 7 (2001) 1869-1879
6. Middleton J.C., and Tipton A.J. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 21 23 (2000) 2335-2346
7. Dhanikula A.B., and Panchagnula R. Localized paclitaxel delivery. Int J Pharm 183 2 (1999) 85-100
8. Radomsky M.L., Brouwer G., Floy B.J., Loury D.J., Chu F., Tipton A.J., et al. The controlled release of ganirelix from ATRIGEL(TM) injectable implant system. Proc Int Symp Control Rel Bioact Mater 20 (1993) 458-459
9. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., and Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release 125 3 (2008) 193-209
10. Fulzele S.V., Satturwar P.M., and Dorle A.K. Study of the biodegradation and in vivo biocompatibility of novel biomaterials. Eur J Pharm Sci 20 1 (2003) 53-61
11. Grayson A.C.R., Voskerician G., Lynn A., Anderson J.M., Cima M.J., and Langer R. Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip. J Biomater Sci Polym Ed 15 10 (2004) 1281-1304
12. Hickey T., Kreutzer D., Burgess D.J., and Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res A 61 2 (2002) 180-187
13. Ratner B.D. Reducing capsular thickness and enhancing angiogenesis around implant drug release systems. J Control Release 78 1-3 (2002) 211-218
14. Fu K., Pack D.W., Klibanov A.M., and Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 17 1 (2000) 100-106
15. Taylor M.S., Daniels A.U., Andriano K.P., and Heller J. 6 Bioabsorbable polymers - in-vitro acute toxicity of accumulated degradation products. J Appl Biomater 5 2 (1994) 151-157
16. Angelova N., and Hunkeler D. Rationalizing the design of polymeric biomaterials. Trends Biotechnol 17 10 (1999) 409-421
17. Pillai O., and Panchagnula R. Polymers in drug delivery. Curr Opin Chem Biol 5 4 (2001) 447-451
18. Dodane V., and Vilivalam V.D. Pharmaceutical applications of chitosan. Pharm Sci Technol Today 1 6 (1998) 246-253
19. Kumar M.N.V.R. A review of chitin and chitosan applications. React Funct Polym 46 1 (2000) 1-27
20. Muzzarelli R.A.A. Biochemical significance of exogenous chitins and chitosans in animals and patients. Carbohydr Polym 20 1 (1993) 7-16
21. Tan H., Chu C.R., Payne K.A., and Marra K.G. Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue engineering. Biomaterials 30 (2009) 2499-2506
22. Cho J., Grant J., Piquette-Miller M., and Allen C. Synthesis and physicochemical and dynamic mechanical properties of a water-soluble chitosan derivative as a biomaterial. Biomacromolecules 7 10 (2006) 2845-2855
23. Mehnert W., and Mader K. Solid lipid nanoparticles - production, characterization and applications. Adv Drug Deliv Rev 47 2-3 (2001) 165-196
24. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4 2 (2005) 145-160
25. Kawaguchi E., Shimokawa K., and Ishii F. Physicochemical properties of structured phosphatidylcholine in drug carrier lipid emulsions for drug delivery systems. Colloid Surface B 62 1 (2008) 130-135
26. Grant J., Blicker M., Piquette-Miller M., and Allen C. Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel. J Pharm Sci USA 94 7 (2005) 1512-1527
27. Ho E.A., Vassileva V., Allen C., and Piquette-Miller M. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. J Control Release 104 1 (2005) 181-191
28. Grant J., Lee H., Soo P.L., Cho J., Piquette-Miller M., and Allen C. Influence of molecular organization and interactions on drug release for an injectable polymer-lipid blend. Int J Pharm 360 1-2 (2008) 83-90
29. Ho E.A., Soo P.L., Allen C., and Piquette-Miller M. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Control Release 117 1 (2007) 20-27
30. Vassileva V., Grant J., De Souza R., Allen C., and Piquette-Miller M. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother Pharmacol 60 6 (2007) 907-914
31. Zahedi P, De Souza R, Piquette-Miller M, Allen C. Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. Int J Pharm, submitted for publication.
32. ten Tije A.J., Verweij J., Loos W.J., and Sparreboom A. Pharmacological effects of formulation vehicles - Implications for cancer chemotherapy. Clin Pharmacokinet 42 7 (2003) 665-685
33. Engels F.K., Mathot R.A.A., and Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drug 18 2 (2007) 95-103
34. Grant J., Tomba J.P., Lee H., and Allen C. Relationship between composition and properties for stable chitosan films containing lipid microdomains. J Appl Polym Sci 103 6 (2007) 3453-3460
35. Soo P.L., Cho J., Grant J., Ho E., Picluette-Miller M., and Allen C. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology. Eur J Pharm Biopharm 69 1 (2008) 149-157
36. Lim S.H., and Hudson S.M. Synthesis and antimicrobial activity of a water-soluble chitosan derivative with a fiber-reactive group. Carbohydr Res 339 2 (2004) 313-319
37. Bhatia S.K., and Yetter A.B. Correlation of visual in vitro cytotoxicity ratings of biomaterials with quantitative in vitro cell viability measurements. Cell Biol Toxicol 24 4 (2008) 315-319
38. Yamamoto A., Honma R., Tanaka A., and Sumita M. Generic tendency of metal salt cytotoxicity for six cell lines. J Biomed Mater Res 47 3 (1999) 396-403
39. Baek H.S., Yoo J.Y., Rah D.K., Han D.W., Lee D.H., Kwon O.H., et al. Evaluation of the extraction method for the cytotoxicity testing of latex gloves. Yonsei Med J 46 4 (2005) 579-583
40. Tan H.T., Dass C.R., and Dunstan D.E. Injectable chitosan hydrogels for localised cancer therapy. J Control Release 126 (2008) 205-216
41. Vian L., Vincent J., Maurin J., Fabre I., Giroux J., and Cano J.P. Comparison of 3 in-vitro cytotoxicity assays for estimating surfactant ocular irritation. Toxicol In Vitro 9 2 (1995) 185-190
42. Marinovich M., Tragni E., Corsini A., and Galli C.L. Quantification of in vitro cytotoxicity of surfactants - correlation with their eye irritation potential. J Toxicol Cutaneous Ocul Toxicol 9 3 (1990) 169-178
43. Mao Z., Ma L., Jiang Y., Yan M., Gao C., and Shen J. N,N,N,-Trimethylchitosan chloride as a gene vector: synthesis and application. Macromol Biosci 7 (2007) 855-863
44. Sonntag N.O.V. The reactions of aliphatic acid chlorides. Chem Rev 52 2 (1953) 237-416
45. Mendes J.B., Campos P.P., Ferreira M.A.N.D., Bakhle Y.S., and Andrade S.P. Host response to sponge implants differs between subcutaneous and intraperitoneal sites in mice. J Biomed Mater Res B 83B 2 (2007) 408-415
46. Yang K.C., Wu C.C., Lin F.H., Qi Z., Kuo T.F., Cheng Y.H., et al. Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas. Xenotransplantation 15 6 (2008) 407-416
47. Hoemann C.D., Sun J., Legare A., McKee M., and Buschmann M. Tissue engineering of cartilage using an injectable and adhesive chitosan-based cell-delivery vehicle. Osteoarthr Cartil 13 4 (2004) 318-329
48. Zareie M., Keuning E.D., ter Wee P.M., Schalkwijk C.G., Beelen R.H.J., and van den Born J. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH. Nephrol Dial Transplant 21 1 (2006) 208-216
49. Park M.S., Heimburger O., Waniewski J., Werynski A., Lee H.B., Bergstrom J., et al. The effect of dialysate acidity on peritoneal solute transport in the rat. Perit Dial Int 15 8 (1995) 312-319
50. Stokes W.S. Humane endpoints for laboratory animals used in toxicity testing. ILAR J 43 (2002) S31-38
51. Ullman-Cullere M., and Foltz C. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 49 3 (1999) 319-323
52. Robitaille R., Dusseault J., Henley N., Desbiens K., Labrecque N., and Halle J.P. Inflammatory response to peritoneal implantation of alginate-poly-l-lysine microcapsules. Biomaterials 26 19 (2005) 4119-4127
53. Walley K.R., Lukacs N.W., Standiford T.J., Strieter R.M., and Kunkel S.L. Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect Immun 65 9 (1997) 3847-3851
54. Anderson J.M. Biological responses to materials. Annu Rev Mater Res 31 (2001) 81-110
55. Shannon C., Thull R., and von Recum A. Types I and III collagen in the tissue capsules of titanium and stainless-steel implants. J Biomed Mater Res 34 3 (1997) 401-408
56. Ungersbock A., Pohler O.E.M., and Perren S.M. Evaluation of soft tissue reactions at the interface of titanium limited contact dynamic compression plate implants with different surface treatments: an experimental sheep study. Biomaterials 17 8 (1996) 797-806
57. Azab A.K., Doviner V., Orkin B., Kleinstem J., Srebnik M., Nissan A., et al. Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat. J Biomed Mater Res A 83A 2 (2007) 414-422
58. Mi F.L., Tan Y.C., Liang H.F., and Sung H.W. In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant. Biomaterials 23 1 (2002) 181-191
59. Drori S., Eytan G.D., and Assaraf Y.G. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane-permeability. Eur J Biochem 228 3 (1995) 1020-1029
60. Lorenz W., Schmal A., Schult H., Lang S., Ohmann C., Weber D., et al. Histamine-release and hypotensive reactions in dogs by solubilizing agents and fatty-acids - analysis of various components in cremophorel and development of a compound with reduced toxicity. Agents Actions 12 1-2 (1982) 64-80
61. Kohane D.S., Tse J.Y., Yeo Y., Padera R., Shubina M., and Langer R. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mater Res A 77A 2 (2006) 351-361
62. Crist S.A., Elzey B.D., Ludwig A.T., Griffith T.S., Staack J.B., Lentz S.R., et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Exp Hematol 32 11 (2004 Nov) 1073-1081
63. Danese S., de la Motte C., Sturm A., Vogel J.D., West G.A., Strong S.A., et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 124 5 (2003 May) 1249-1264
64. Cesta M.F. Normal structure, function, and histology of the spleen. Toxicol Pathol 34 5 (2006) 455-465
65. Jones K.S. Effects of biomaterial-induced inflammation on fibrosis and rejection. Semin Immunol 20 2 (2008) 130-136
66. Rouabhia M., Gilbert V., Wang H., and Subirade M. In vivo evaluation of whey protein-based biofilms as scaffolds for cutaneous cell cultures and biomedical applications. Biomed Mater 2 (2007) S38-S44
67. Fournier E., Passirani C., Montero-Menei C.N., and Benoit J.P. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 24 19 (2003) 3311-3331